LY2835219
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neoplasm Metastasis
Conditions
Neoplasm Metastasis, Lymphoma
Trial Timeline
Dec 18, 2013 → Aug 21, 2019
NCT ID
NCT02014129About LY2835219
LY2835219 is a phase 1 stage product being developed by Eli Lilly for Neoplasm Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02014129. Target conditions include Neoplasm Metastasis, Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02059148 | Phase 1 | Completed |
| NCT02014129 | Phase 1 | Completed |
Competing Products
20 competing products in Neoplasm Metastasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AB0024 | Gilead Sciences | Phase 1 | 32 |
| TTI-237 | Pfizer | Phase 1 | 32 |
| 852A | Pfizer | Phase 1 | 32 |
| EO-3021 + Ramucirumab (CYRAMZA®) + Dostarlimab | CSPC Pharmaceutical Group Limited | Phase 1 | 32 |
| LY2780301 | Eli Lilly | Phase 1 | 33 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| IMC-3C5 | Eli Lilly | Phase 1 | 33 |
| LY3295668 | Eli Lilly | Phase 1/2 | 41 |
| Abemaciclib + Clarithromycin | Eli Lilly | Phase 1 | 33 |
| Abemaciclib + Fulvestrant | Eli Lilly | Phase 2 | 52 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | 41 |
| Fulvestrant + Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Fulvestrant + Placebo | Eli Lilly | Phase 3 | 77 |
| Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + Leucovorin | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 33 |
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| enzastaurin + gemcitabine | Eli Lilly | Phase 2 | 52 |
| Abemaciclib + Darolutamide + LHRH agonist/antagonist | Eli Lilly | Phase 1 | 33 |